Allogeneic bone marrow transplantation for aplastic anemia | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Allogeneic bone marrow transplantation for aplastic anemia

Journal Title: 
International Journal of Hematology
Primary Author: 
Storb R
Storb R
Original Publication Date: 
Wednesday, December 28, 2022
Bone Marrow Disease(s): 

After more than 60 years of intense research in allogeneic hematopoietic cell transplantation (HCT), this therapy has progressed from one that was fraught with seemingly insurmountable complications to a standard treatment of patients with aplastic anemia. During the 1970s and 1980s, HCT donors were almost exclusively HLA-identical siblings. Subsequent advances in the understanding of the complexity of the HLA region along with the development of molecular HLA typing and the establishment of unrelated volunteer donor registries have resulted in an ever-increasing use of such donors. Most recent breakthroughs have enabled HLA-haploidentical HCT and, thereby, finding donors for nearly every patient. The outstanding outcomes reported with any of the donor options have made allogeneic HCT the preferred treatment over immunosuppressive therapy.